Interferograms plotted with reference change value (RCV) may facilitate the management of hemolyzed samples
Interferograms plotted with RCV to manage hemolysis
Abstract
Background: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE) have recommended an algorithm based on the reference change value (RCV) to evaluate hemolysis. We utilized this algorithm to analyze hemolysis-sensitive parameters.
Methods: Two tubes of blood were collected from each of the 10 participants, one of which was subjected to mechanical trauma while the other was centrifuged directly. Subsequently, the samples were diluted with the participant's hemolyzed sample to obtain the desired hemoglobin concentrations (0, 1, 2, 4, 6, 8, and 10 g/L). ALT, AST, K, LDH, T.Bil tests were performed using Beckman Coulter AU680 analyzer. The analytical and clinical cut-offs were based on the biological variation for the allowable imprecision and RCV. The algorithms could report the values directly below the analytical cut-off or those between the analytical and clinical cut-offs with comments. If the change was above the clinical cut-off, the test was rejected. The linear regression was used for interferograms, and the hemoglobin concentrations corresponding to cut-offs were calculated via the interferograms.
Results: The RCV was calculated as 29.6% for ALT. Therefore, ALT should be rejected in samples containing >5.9 g/L hemoglobin. The RCVs for AST, K, LDH, and T.Bil were calculated as 27.9%, 12.1%, 19.2%, and 61.2%, while the samples' hemoglobin concentrations for test rejection were 0.8, 1.6, 0.5, and 2.2 g/L, respectively.
Conclusions: Algorithms prepared with RCV could provide evidence-based results and objectively manage hemolyzed samples.
References
2. Plebani M, Laposata M, Lippi G. Driving the route of laboratory medicine: a manifesto for the future. Intern Emerg Med. 2019; 11–4.
3. Plebani M, Carraro P. Mistakes in a stat laboratory: Types and frequency. Clin Chem. 1997; 43(8):1348–51.
4. Carraro P, Plebani M. Errors in a stat laboratory: Types and frequencies 10 years later. Clin Chem. 2007; 53(7):1338–42.
5. Lippi G, von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. Diagn Berl Ger. 2019; 6(1):25–31.
6. Mrazek C, Lippi G, Keppel MH, Felder TK, Oberkofler H, Haschke-Becher E, et al. Errors within the total laboratory testing process, from test selection to medical decision-making – A review of causes, consequences, surveillance and solutions. Biochem Medica. 2020; 30(2):1–19.
7. Phelan MP, Reineks EZ, Schold JD, Hustey FM, Chamberlin J, Procop GW. Preanalytic factors associated with hemolysis in emergency department blood samples. Arch Pathol Lab Med. 2018; 142(2):229–35.
8. Carraro P, Servidio G, Plebani M. Hemolyzed specimens: A reason for rejection or a clinical challenge? Clin Chem. 2000; 46(2):306–7.
9. Heireman L, Van Geel P, Musger L, Heylen E, Uyttenbroeck W, Mahieu B. Causes, consequences and management of sample hemolysis in the clinical laboratory. Clin Biochem. 2017; 50(18):1317–22.
10. Simundic AM, Nikolac N, Ivankovic V, Ferenec-Ruzic D, Magdic B, Kvaternik M, et al. Comparison of visual vs. automated detection of lipemic, icteric and hemolyzed specimens: Can we rely on a human eye? Clin Chem Lab Med. 2009; 47(11):1361–5.
11. Luksic AH, Nikolac Gabaj N, Miler M, Dukic L, Bakliza A, Simundic AM. Visual assessment of hemolysis affects patient safety. Clin Chem Lab Med. 2018; 56(4):574–81.
12. Simundic AM, Baird G, Cadamuro J, Costelloe SJ, Lippi G. Managing hemolyzed samples in clinical laboratories. Crit Rev Clin Lab Sci. 2020; 57(1):1–21.
13. Lippi G, Cervellin G, Favaloro EJ, Plebani M. In Vitro and In Vivo Hemolysis: An Unresolved Dispute in Laboratory Medicine. Berlin/Boston: Walter de Gruyter GmbH; 2012.
14. CLSI. Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline. CLSI document C56-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
15. Fraser CG. Test result variation and the quality of evidence-based clinical guidelines. Clin Chim Acta. 2004; 346(1):19–24.
16. Lippi G, Cadamuro J, Von Meyer A, Simundic AM. Practical recommendations for managing hemolyzed samples in clinical chemistry testing. Clin Chem Lab Med. 2018; 56(5):718–27.
17. EFLM Biological Variation Database. Available from: https://biologicalvariation.eu/ Accessed at: 15.06.2020.
18. Westgard Biological Variation Database. Available from: https://www.westgard.com/biodatabase1.htm Accessed at: 15.06.2020.
19. Lippi G, Giavarina D, Gelati M, Salvagno GL. Reference range of hemolysis index in serum and lithium-heparin plasma measured with two analytical platforms in a population of unselected outpatients. Clin Chim Acta. 2014 Feb; 429:143–6.
20. Perović A, Dolčić M. Influence of hemolysis on clinical chemistry parameters determined with Beckman Coulter tests–detection of clinically significant interference. Scand J Clin Lab Invest. 2019; 79(3):154–9.
21. Monneret D, Mestari F, Atlan G, Corlouer C, Ramani Z, Jaffre J, et al. Hemolysis indexes for biochemical tests and immunoassays on Roche analyzers: Determination of allowable interference limits according to different calculation methods. Scand J Clin Lab Invest. 2015; 75(2):162–9.
22. Du Z, Liu JQ, Zhang H, Bao BH, Zhao RQ, Jin Y. Determination of hemolysis index thresholds for biochemical tests on Siemens Advia 2400 chemistry analyzer. J Clin Lab Anal. 2019; 33(4):1–7.
23. Knezevic CE, Ness MA, Tsang PHT, Tenney BJ, Marzinke MA. Establishing hemolysis and lipemia acceptance thresholds for clinical chemistry tests. Clin Chim Acta. 2020; 510(July):459–65.
24. Gils C, Sandberg MB, Nybo M. Verification of the hemolysis index measurement: imprecision, accuracy, measuring range, reference interval and impact of implementing analytically and clinically derived sample rejection criteria. Scand J Clin Lab Invest. 2020; 80(7):580–9.
25. Koseoglu M, Hur A, Atay A, Cuhadar S. Effects of hemolysis interferences on routine biochemistry parameters. Biochem Medica. 2011; 21(1):79–85.
26. von Meyer A, Cadamuro J, Lippi G, Simundic AM. Call for more transparency in manufacturers declarations on serum indices: On behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). Clin Chim Acta. 2018; 484(March):328–32.
27. Cadamuro J, Lippi G, von Meyer A, Ibarz M, van Dongen E, Lases5, et al. European survey on preanalytical sample handling - Part 1: How do European laboratories monitor the preanalytical phase? On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase. Biochem Medica. 2019; 29(2):20704.
28. Cadamuro J, Lippi G, von Meyer A, Ibarz M, van Dongen-Lases E, Cornes M, et al. European survey on preanalytical sample handling – part 2: Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European federation of clinical chemistry and laboratory medicine (EFLM). Biochem Medica. 2019; 29(2):334–45.
29. Lippi G, Plebani M. Integrated diagnostics: The future of laboratory medicine? Biochem Medica. 2020; 30(1):1–13.
30. CLSI. Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood; Approved Standard—Third Edition. CLSI document H15-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2000.
31. Lippi G, Cattabiani C, Bonomini S, Bardi M, Pipitone S, Aversa F. Preliminary evaluation of complete blood cell count on Mindray BC-6800. Clin Chem Lab Med. 2013; 51(4):2012–4.
Copyright (c) 2021 Kamil Taha Uçar, Abdulkadir Çat, Alper Gümüş, Nilhan Nurlu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.